Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.
Ideggyogy Sz
; 74(11-12): 379-387, 2021 Nov 30.
Article
em En
| MEDLINE
| ID: mdl-34856086
ABSTRACT
In aging societies, the morbidity and mortality of dementia is increasing at a significant rate, thereby imposing burden on healthcare, economy and the society as well. Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer's dementias too. The aim of our work was to provide a comprehensive summary about the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer's and non-Alzheimers's dementias.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Memantina
/
Doença de Alzheimer
Tipo de estudo:
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Ideggyogy Sz
Ano de publicação:
2021
Tipo de documento:
Article